ROCKVILLE, Md., March 4 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that it will report its 2009 year-end financial results in a press release to be issued after 8:00 a.m. local time on Friday, March 12, 2010. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, March 12, 2010. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the overview of the financial results. The dial-in number for the conference call is 1 (866) 804 3550 (U.S. or Canada) or 1 (703) 639-1330 (International).
About Novavax, Inc.
Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
CONTACT: Tricia J. Richardson, Senior Manager, Investor Relations of
Novavax, Inc., +1-240-268-2031
Web site: http://www.novavax.com/
